← Browse by Condition
Medical Condition

non hodgkin lymphoma

Total Trials
19
Recruiting Now
19
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
NCT06418204
Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Enrollment
2,000 pts
Location
United States, Puert...
Sponsor
Wake Forest University Health ...
View Trial →
NCT05006716 Phase 1, Phase 2
Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Enrollment
614 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT05605119 Phase 1
Recruiting

First in Human, Dose Escalation, Dose Expansion Study of AUR105

Enrollment
40 pts
Location
India
Sponsor
Aurigene Discovery Technologie...
View Trial →
NCT04739813 Phase 1
Recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Enrollment
55 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05031897 Phase 2
Recruiting

Two Step Haplo With Radiation Conditioning

Enrollment
63 pts
Location
United States
Sponsor
Thomas Jefferson University
View Trial →
NCT05529069 Phase 2
Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Enrollment
30 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06219356 Phase 1
Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Enrollment
110 pts
Location
China
Sponsor
Hangzhou GluBio Pharmaceutical...
View Trial →
NCT06131801
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Enrollment
30 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...
View Trial →
NCT05283720 Phase 2
Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Enrollment
496 pts
Location
United States, China...
Sponsor
Genmab
View Trial →
NCT06088654 Phase 1, Phase 2
Recruiting

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Enrollment
184 pts
Location
United States, Austr...
Sponsor
Innate Pharma
View Trial →
NCT05839210
Recruiting

Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

Enrollment
140 pts
Location
United States
Sponsor
University of Miami
View Trial →
NCT05389423 Phase 1
Recruiting

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Enrollment
25 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT06004011
Recruiting

AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)

Enrollment
4,100 pts
Location
Zambia
Sponsor
Implenomics
View Trial →
NCT02393157 Phase 2
Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Enrollment
25 pts
Location
United States
Sponsor
New York Medical College
View Trial →
NCT07283822 Phase 2
Recruiting

Amping up With PemJAK

Enrollment
53 pts
Location
United States
Sponsor
Seda S. Tolu
View Trial →
NCT05921812
Recruiting

Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients

Enrollment
70 pts
Location
Egypt
Sponsor
Sohag University
View Trial →
NCT03050268
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Enrollment
1,500 pts
Location
United States
Sponsor
St. Jude Children's Research H...
View Trial →
NCT06180174 Phase 1
Recruiting

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Enrollment
24 pts
Location
China
Sponsor
Chongqing Precision Biotech Co...
View Trial →
NCT06116110
Recruiting

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Enrollment
150 pts
Location
United States
Sponsor
Miltenyi Biomedicine GmbH
View Trial →